Publications
Microfluidic preparation of composite hydrogel microparticles for the staining of microalgal cells*
Colloids and Surfaces B Biointerfaces
(2022)
221
113026
Development of potent inhibitors by fragment‐linking strategies
Chemical Biology & Drug Design
(2022)
100
469
(doi: 10.1111/cbdd.14120)
Structural Characterization of Mycobacterium abscessus Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design.
Front Mol Biosci
(2022)
9
880432
(doi: 10.3389/fmolb.2022.880432)
Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections
RSC medicinal chemistry
(2022)
13
392
(doi: 10.1039/d1md00359c)
Discovery of Novel Inhibitors of Uridine Diphosphate- N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients
J Med Chem
(2022)
65
2149
(doi: 10.1021/acs.jmedchem.1c01684)
Development of Inhibitors of SAICAR Synthetase (PurC) from <i>Mycobacterium abscessus</i> Using a Fragment-Based Approach.
ACS infectious diseases
(2022)
8
296
(doi: 10.1021/acsinfecdis.1c00432)
A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen)
European Journal of Medicinal Chemistry
(2022)
230
114105
(doi: 10.1016/j.ejmech.2022.114105)
A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis
Computational and structural biotechnology journal
(2021)
19
3491
(doi: 10.1016/j.csbj.2021.06.006)
Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity
ACS Infectious Diseases
(2021)
7
1666
(doi: 10.1021/acsinfecdis.0c00904)
- ‹ previous
- Page 2